Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
1991-3-22
|
pubmed:abstractText |
Previous studies have indicated that cyst fluid of ovarian tumors contains 2 trypsinogen isoenzymes, called tumor-associated trypsinogen-I (TAT-I) and trypsinogen-2 (TAT-2), the levels of which correlate with the degree of malignancy of the tumors. In addition, these cyst fluids contain large amounts of tumor-associated trypsin inhibitor (TATI), which is also expressed in many other human tumors. In the present study we examined the production of TAT-I, TAT-2 and TATI in 9 established tumor-cell lines. TAT-2 was produced by 5 cell lines. Its concentration in the conditioned medium of COLO 205 colon adenocarcinoma cells, K-562 erythroleukemia cells and fibrosarcoma cell lines HT 1080, 8387 and A 9733 was 460 micrograms/l, 9.8 micrograms/l, 21 micrograms/l, 8.8 micrograms/l and 0.24 micrograms/l, respectively. TAT-I was detectable in the conditioned medium of COLO 205 and HT 1080 cells at concentrations of 64 micrograms/l and 0.5 micrograms/l, respectively. TATI was detected only in the media of COLO 205 cells at a concentration of 23 micrograms/l. TAT-2 zymogen was purified from the conditioned medium of COLO 205 and HT 1080 cells by immunoaffinity chromatography. According to its aminoterminal amino acid sequence, a molecular mass of 28 kDa by SDS-PAGE, elution pattern in ion-exchange chromatography and ability to be activated by enteropeptidase, the zymogen is identical to that previously isolated from cyst fluid of ovarian tumors. In addition, we found that TAT-2 secretion could be down-regulated by dexamethasone in HT 1080 cells but not in COLO 205 cells. The abundant production of TAT-2 isoenzyme in different cancer cell lines suggests that it could contribute to the increased proteolytic activity of many human tumors.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0020-7136
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
20
|
pubmed:volume |
47
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
592-6
|
pubmed:dateRevised |
2007-7-24
|
pubmed:meshHeading |
pubmed-meshheading:1995487-Carcinoma,
pubmed-meshheading:1995487-Colonic Neoplasms,
pubmed-meshheading:1995487-Dexamethasone,
pubmed-meshheading:1995487-Extracellular Matrix,
pubmed-meshheading:1995487-Fibrosarcoma,
pubmed-meshheading:1995487-Humans,
pubmed-meshheading:1995487-Isoenzymes,
pubmed-meshheading:1995487-Leukemia,
pubmed-meshheading:1995487-Trypsinogen,
pubmed-meshheading:1995487-Tumor Cells, Cultured
|
pubmed:year |
1991
|
pubmed:articleTitle |
Human colon carcinoma, fibrosarcoma and leukemia cell lines produce tumor-associated trypsinogen.
|
pubmed:affiliation |
Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Finland.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|